Mitoxantrone Hydrochloride Liposome for Neuromyelitis Optica Spectrum Disorders Treatment
Summary
The USPTO published patent application US20260108478A1 on April 23, 2026, covering mitoxantrone hydrochloride liposome compositions for treating neuromyelitis optica spectrum disorders. The application includes pharmaceutical compositions and methods of treatment, with animal and clinical test results demonstrating safety and efficacy. This represents an early-stage IP filing with no immediate compliance implications for the pharmaceutical sector.
“Animal and clinical test results show that mitoxantrone hydrochloride liposome is safe and effective in treatment of neuromyelitis optica spectrum disorders.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 193 changes logged to date.
What changed
The USPTO published patent application US20260108478A1 covering the use of mitoxantrone hydrochloride liposome for treating neuromyelitis optica spectrum disorders. The application includes both the pharmaceutical composition claims and treatment methods. The inventors claim safety and efficacy based on animal and clinical test results. For pharmaceutical companies and biotech firms developing treatments for autoimmune neurological conditions, this publication establishes prior art in the liposomal drug delivery space for neuromyelitis optica. No immediate compliance actions are required.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME
Application US20260108478A1 Kind: A1 Apr 23, 2026
Inventors
Chunlei LI, Jiaqi LIU, Yanhui LI, Yulou YU, Xiugao YANG, Mengmeng LI, Guohua WU, Yanling DU, Meng ZHOU, Shixia WANG, Chao LI
Abstract
The present application provides use of mitoxantrone hydrochloride liposome in treatment of neuromyelitis optica spectrum disorders. The present application further provides a method for treating neuromyelitis optica spectrum disorders in an individual. The method comprises administering to the individual a therapeutically effective amount of mitoxantrone hydrochloride liposome or a pharmaceutical composition comprising mitoxantrone hydrochloride liposome. Animal and clinical test results show that mitoxantrone hydrochloride liposome is safe and effective in treatment of neuromyelitis optica spectrum disorders.
CPC Classifications
A61K 31/136 A61K 9/0019 A61K 9/127 A61P 27/02
Filing Date
2023-07-19
Application No.
18996594
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.